Please login to the form below

Not currently logged in
Email:
Password:

Novartis to submit Afinitor for approval

Novartis is to submit its advanced breast cancer drug Afinitor for marketing approval following positive results from a phase III study

Novartis is to submit its advanced breast cancer drug Afinitor (everolimus) for marketing approval following positive results from a phase III study.

The BOLERO-2 was stopped early after interim results showed that the primary end point of significant progression-free survival compared to placebo plus exemestane had already been met.

The study involved postmenopausal women with estrogen receptor-positive locally-advanced or metastatic breast cancer, whose disease has progressed, despite initial endocrine therapy.

Hervé Hoppenot, president, Novartis Oncology, described how woman can develop resistance to endocrine therapy, and that there is a "significant need" for new treatment options.

He said: "Based on these study results, this combination has the potential to extend the time until chemotherapy is needed for these patients."

Novartis has said it will present the results at an upcoming medical conference, with plans for regulatory approval submission to be submitted by the end of 2011.

5th July 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Streaming Well

Streaming Well is a healthcare focused, award-winning video production company which operates in the US and Europe....

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics